or
Looking to list your PhD opportunities? Log in here.
Dr Natalie Poulter completed her undergraduate studies at the University of Birmingham, earning a BSc in Biological Sciences with Study in Continental Europe in 2005. During her year abroad, she studied at the Université Paul Sabatier in Toulouse, France, where she focused on genetics, molecular cell biology, and plant biotechnology. Dr Poulter obtained her PhD in Plant Cell Biology in 2009, investigating the role of the cytoskeleton in the self-incompatibility response of poppy, under the supervision of Professor Noni Franklin-Tong (FRS) at the University of Birmingham. Following her PhD, Dr Poulter transitioned from plant biology to mammalian cell research, where she studied cell migration, endocytosis, and cell signalling, employing advanced microscopy techniques. Upon joining the Birmingham Platelet Group, her research shifted towards the role of platelets in thrombosis and haemostasis, focusing on platelet surface receptors, their signalling pathways, and their influence on thrombus formation. Recently, she has engaged in translating her research findings into the development of novel therapeutics aimed at treating cardiovascular conditions such as heart attacks and strokes. In addition to her research, Dr Poulter has actively promoted ''Team Science'' within her department and beyond. She served as the UoB Team Science Lead for COMPARE from 2017 to 2021, fostering collaboration between the Universities of Birmingham and Nottingham. This initiative received recognition from the Academy of Medical Sciences in their 2019 report as an exemplary Team Science training initiative. Dr Poulter also held the position of Team Science Lead for the British Heart Foundation Accelerator Award for Birmingham. Currently, Dr Poulter is the postgraduate research (PGR) Lead for Cardiovascular Sciences, responsible for coordinating and managing research degree programmes and organising enrichment events for PGR students. She has supervised six PhD students to completion and has contributed as the Deputy Coordinator for the TAPAS European Commission Horizon 2020 Marie Sklodowska-Curie Innovative Training Network (ITN). Dr Poulter is open to inquiries from prospective PhD students interested in receptor signalling, platelet activation, and the development of anti-platelet therapies.
Dr Natalie Poulter''s research focuses on the signalling pathways that lead to platelet activation and thrombus formation. Her work aims to translate this understanding into anti-platelet therapies for treating heart attacks and strokes. She investigates the cellular mechanisms involved in platelet activation, particularly the role of platelet surface receptors and their signalling pathways, including ITAM-related receptors like the collagen receptor GPVI. Dr Poulter employs advanced microscopy techniques, including super-resolution microscopy, to study receptor clustering and thrombus architecture. Additionally, she is involved in developing new biologics to inhibit platelet activation in response to physiological activators such as atherosclerotic plaque. Other research interests include the effects of rare genetic variants in platelet receptors on platelet function, particularly in patients with bleeding disorders.
Professor Steve P. Watson is an Emeritus British Heart Foundation Professor in Cardiovascular Sciences and Cellular Pharmacology at the University of Birmingham. He is the Head of the Birmingham Platelet Group, which comprises over 40 researchers, including more than 10 principal investigators, focusing on the haemostatic and non-haemostatic functions of platelets in health and disease. Professor Watson trained at the Universities of Leeds and Cambridge before completing postdoctoral studies at Burroughs Wellcome in North Carolina. In 1985, he joined the Department of Pharmacology at the University of Oxford, where he received a series of competitive fellowships, including a Royal Society University Research Fellowship. In 2004, he transitioned to a British Heart Foundation Professorship at the University of Birmingham. His research interests centre on the mechanisms of platelet activation by tyrosine kinase-linked receptors, particularly CLEC-2, FcgammaRIIA, GPVI, and PEAR1. He is also involved in developing novel antiplatelet agents targeting these receptors in thrombo-inflammatory diseases. Professor Watson is the founding Co-Director of The Centre of Membrane Proteins and Receptors (COMPARE), a collaboration between the Universities of Birmingham and Nottingham aimed at innovating methods for visualising single membrane proteins and identifying new strategies for preventing and treating cardiovascular disease. He is a Fellow of the Academy of Medical Sciences since 2002 and was awarded the Nature/Nesta mid-career award for creative mentoring in 2006.
Professor Watson''s research focuses on the mechanisms of platelet activation by tyrosine kinase-linked receptors, specifically CLEC-2, FcgammaRIIA, GPVI, and PEAR1. He is involved in developing novel antiplatelet agents that target these receptors in thrombo-inflammatory diseases. His work employs a multi- and inter-disciplinary approach, utilising advanced microscopy, molecular modelling, crystallography, cell line studies, and protein phosphorylation to investigate receptor activation mechanisms. Professor Watson has developed high affinity antibodies and nanobodies that block CLEC-2 and GPVI, aiming to translate these findings into early phase clinical trials. He is also researching the mechanisms of thrombosis in patients with vaccine-induced immune thrombosis and thrombocytopenia. His research is supported by various funding bodies, including the BBSRC, British Heart Foundation, MRC, NIHR, and Wellcome Trust.